Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 9/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | TYMS | P04818 | 2/20 | 0.74 |
| ▸ | POLB | P06746 | 2/20 | 0.74 |
| ▸ | HPGD | P15428 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.74 |
| ▸ | GAA | P10253 | 1/20 | 0.74 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.74 |
| ▸ | TLR4 | O00206 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | TP53 | P04637 | 1/20 | 0.71 |
| ▸ | GLA | P06280 | 1/20 | 0.71 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aminopterin SCHEMBL9514067 | 1.00 | DHFR (0.76) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| Aminopterin SCHEMBL20769794 | 1.00 | DHFR (0.76) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| Aminopterin SCHEMBL29443569 | 1.00 | DHFR (0.76) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| Aminopterin SCHEMBL8887 | 1.00 | DHFR (0.76) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| Aminopterin SCHEMBL8161477 | 1.00 | DHFR (0.76) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| Aminopterin SCHEMBL29398079 | 1.00 | DHFR (0.76) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| Aminopterin SCHEMBL23581239 | 0.99 | DHFR (0.75) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| Aminopterin SCHEMBL5024596 | 0.99 | DHFR (0.75) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| Aminopterin SCHEMBL2504074 | 0.99 | DHFR (0.75) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| Aminopterin SCHEMBL2387187 | 0.99 | DHFR (0.75) | DHFRKDM4EMEN1ALDH1A1TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109675048-A | A kind of anticancer prodrug liposome and artemisine liposome Nano medication | 中国科学院化学研究所 | 2019-04-26 | — | — | CN | claimed |
| EP-2002846-B1 | Combination therapy using an IL-1 inhibitor for treating IL-1 mediated diseases | AMGEN INC (US) | 2017-01-25 | — | — | EP | claimed |
| US-20090203609-A1 | Use of IL-1 inhibitors for treating IL-1 mediated diseases | AMGEN INC. | 2009-08-13 | — | — | US | claimed |
| US-20040044001-A1 | Use of II-1 inhibitors for treating II-1 mediated diseases | AMGEN INC. | 2004-03-04 | — | — | US | claimed |
| US-20030072756-A1 | Combination therapy using an IL-1 inhibitor and methotrexate | AMGEN INC. | 2003-04-17 | — | — | US | claimed |
| JP-2002509529-A | — | — | 2002-03-26 | — | — | JP | claimed |
| EP-0949931-A1 | COMBINATION THERAPY USING AN IL-1 INHIBITOR FOR TREATING IL-1 MEDIATED DISEASES | AMGEN INC. (US) | 1999-10-20 | — | — | EP | claimed |
| WO-1998024477-A1 | COMBINATION THERAPY USING AN IL-1 INHIBITOR FOR TREATING IL-1 MEDIATED DISEASES | AMGEN INC. (US) | 1998-06-11 | — | — | WO | claimed |
| US-20230201203-A1 | METHODS OF TREATMENT USING ANTIFOLATES AND PHARMACEUTICAL FORMULATIONS COMPRISING ANTIFOLATES | EMPHASCIENCE, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230129487-A1 | SMALL MOLECULE BCL-2 FUNCTIONAL CONVERTERS AS CANCER THERAPEUTICS | OREGON STATE UNIVERSITY (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230129487-A1 | SMALL MOLECULE BCL-2 FUNCTIONAL CONVERTERS AS CANCER THERAPEUTICS | OREGON STATE UNIVERSITY (US) | 2023-04-27 | — | — | US | disclosed |
| CN-115942978-A | Antibody-drug conjugates comprising anti-B7-H3 antibodies | 尹图赛利有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-109562170-B | anti-CD 98 antibodies and antibody drug conjugates | 艾伯维公司（US） | 2023-01-13 | — | — | CN | disclosed |
| US-11419843-B2 | Small molecule BCL-2 functional converters as cancer therapeutics | OREGON STATE UNIVERSITY (US) | 2022-08-23 | — | — | US | disclosed |
| WO-1998024463-A2 | COMBINATION THERAPY USING A TNF BINDING PROTEIN FOR TREATING TNF-MEDIATED DISEASES | AMGEN INC. (US) | 1998-06-11 | — | — | WO | disclosed |
| US-4767859-A | Process for the preparation of pteridine derivatives | RHONE-POULENC SANTE (FR) | 1988-08-30 | — | — | US | disclosed |
| US-4268516-A | [1]Benzothiopyrano[4,3-c]pyrazoles as immunoregulatory agents | PFIZER INC. (US) | 1981-05-19 | — | — | US | disclosed |
| US-4079056-A | REACTING 2,4-DIAMINO-6-PTERIDINE-METHANOL-HBR WITH TRIPHENYLPHOSPHINE DIBROMIDE OR PHOSPHORUS TRIBROMIDE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1978-03-14 | — | — | US | disclosed |
| US-4077957-A | INTERMEDIATE FOR METHOTREXATE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1978-03-07 | — | — | US | disclosed |
| US-3981983-A | Rapid, radiochemical-ligand binding assay for methotrexate | CASE WESTERN RESERVE UNIVERSITY (US) | 1976-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11419843-B2 | Small molecule BCL-2 functional converters as cancer therapeutics | BCL2, BCL2L1, BCL2L13 | DHFR 232/4885KDM4E 3276/4885MEN1 2362/4885 |
| US-20040044001-A1 | Use of II-1 inhibitors for treating II-1 mediated diseases | IL1A, IL1B, IL1R1 | DHFR 28/4885KDM4E 2479/4885MEN1 791/4885 |
| US-20090203609-A1 | Use of IL-1 inhibitors for treating IL-1 mediated diseases | IL1A, IL1B, IL1R1 | DHFR 26/4885KDM4E 1774/4885MEN1 728/4885 |
| US-20230129487-A1 | SMALL MOLECULE BCL-2 FUNCTIONAL CONVERTERS AS CANCER THERAPEUTICS | BCL2, BCL2L1, BCL2L13 | DHFR 232/4885KDM4E 3276/4885MEN1 2362/4885 |
| US-20030072756-A1 | Combination therapy using an IL-1 inhibitor and methotrexate | IL1A, IL1B, IL1RN | DHFR 20/4885KDM4E 1432/4885MEN1 993/4885 |
| US-20230201203-A1 | METHODS OF TREATMENT USING ANTIFOLATES AND PHARMACEUTICAL FORMULATIONS COMPRISING ANTIFOLATES | DHFR, MTHFD1, OAT | DHFR 1/4885KDM4E 4073/4885MEN1 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.